Low-dose Btk inhibitors selectively block platelet activation by CLEC-2

Inhibitors of Bruton tyrosine kinase (Btk) have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLCγ2 in human platelets. Activation is also blocke...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Nicolson, Phillip L.R., Nock, Sophie H., Hinds, Joshua, Garcia-Quintanilla, Lourdes, Smith, Christopher W., Campos, Joana, Brill, Alexander, Pike, Jeremy A., Khan, Abdullah O., Poulter, Natalie S., Kavanagh, Deidre M., Watson, Stephanie, Watson, Callum N., Clifford, Hayley, Huissoon, Aarnoud P., Pollitt, Alice Y., Eble, Johannes A., Pratt, Guy, Watson, Steve P., Hughes, Craig E.
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776357/
https://ncbi.nlm.nih.gov/pubmed/31949019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.218545
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados